- June 25, 2024CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 24, 2024-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive topline results from its…
- April 23, 2024Catch up on the latest happenings in our spring newsletter here!
- January 18, 2024Explore the most recent updates in the 2024 Winter Newsletter.
- December 27, 2023US FDA approval based on NEURO-TTRansform Phase III results showing WAINUA demonstrated consistent and sustained benefit improving neuropathy impairment and…
- October 12, 2023Be sure to catch up on the latest happenings in our fall newsletter here!
- July 17, 2023PALO ALTO, Calif., July 17, 2023 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), is a commercial-stage…
- July 13, 2023Be sure to catch up on the latest happenings in our summer newsletter here!
- May 25, 2023By Shelley Wood MAY 23, 2023 PRAGUE, Czechia—A phase I, randomized, double-blind trial of an intravenous antibody in transthyretin amyloid (ATTR)…
- May 3, 2023Oxford, UK, April 26th, 2023 — Ultromics, a leader in the field of artificial intelligence-powered diagnostics for heart failure, has been…
- April 24, 2023WILMINGTON, Del.--(BUSINESS WIRE)--Detailed results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca…
7151 N. Main St. Ste. 2 Clarkston, MI 48346
248-922-9610